EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

Emanuel Raschi, Simone Rossi, Andrea De Giglio, Michele Fusaroli, Flavio Burgazzi, Rita Rinaldi, Luciano Potena

Drug Safety · 2023

DOI: 10.1007/s40264-023-01320-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Safety, 2023. Verfasst von Emanuel Raschi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. e…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Myocarditis, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalMyocarditisNeoplasmsHumansImmune Checkpoint InhibitorsMedical Oncology

Substanzen

Immune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy. emanuel.raschi@unibo.it.
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Unit of Heart Failure and Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Raschi, E., Rossi, S., De Giglio, A., Fusaroli, M., Burgazzi, F., Rinaldi, R., & Potena, L. (2023). Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Safety. https://doi.org/10.1007/s40264-023-01320-5

Vancouver

Raschi E, Rossi S, De Giglio A, Fusaroli M, Burgazzi F, Rinaldi R, et al. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. Drug Safety. 2023. doi:10.1007/s40264-023-01320-5

BibTeX
@article{Raschi2023,
  author = {Raschi, Emanuel and Rossi, Simone and De Giglio, Andrea and Fusaroli, Michele and Burgazzi, Flavio and Rinaldi, Rita and Potena, Luciano},
  title = {Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians},
  journal = {Drug Safety},
  year = {2023},
  doi = {10.1007/s40264-023-01320-5}
}
Kostenlos starten →